↓ Read PDF
01 · ABSTRACT

Abstract

Addictive disorders are often difficult to treat and show high relapse rates. Particularly, alcohol use disorder presents a major treatment challenge leading to severe physical and mental health impacts. So far, pharmacological treatment options are limited. Agonists of the glucagon-like peptide-1 receptor are anti-hyperglycemic and weight-reducing drugs that have anti-inflammatory properties and can modulate brain reward pathways. Mounting evidence suggests that glucagon-like peptide-1 receptor agonists may have the potential to treat addictive disorders. Preclinical research demonstrated that glucagon-like peptide-1 receptor agonists influence addiction primarily by reducing dopaminergic activation in brain reward pathways. The aim of this review is to give an insight into the neurobiological mechanisms by which glucagon-like peptide-1 receptor agonists influence addiction and to evaluate their effectiveness across different substance use disorders and behavioral addictions in humans.

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 14 No 2 (2026): Vol.14, Issue 2, February 2026
SectionReview Articles
Published24 February 2026
DOI10.18103/mra.v14i2.7249
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 4.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

SB

Sigrid Breit

University Hospital of Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗